Cyclophosphamide Alternatives Compared
| Cyclophosphamide | Kesimpta (ofatumumab) | Copaxone (glatiramer) |
|
|---|
| Cyclophosphamide | Kesimpta (ofatumumab) | Copaxone (glatiramer) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Breast Cancer, Brain Tumor, Acute Lymphocytic Leukemia, Acute Nonlymphocytic Leukemia, Bullous Pemphigoid, Burkitt Lymphoma, Cervical Cancer, Chronic Lymphocytic Leukemia, Chronic... View more |
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
Prescription only
Copaxone is a combination of four amino acids that may be given to treat relapsing forms of multiple sclerosis in adults. It has been shown to significantly reduce the number of relapses but may be... View more |
||||||||||||||||||||||||
| More about Cyclophosphamide | More about Kesimpta (ofatumumab) | More about Copaxone (glatiramer) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Cyclophosphamide has an average rating of 8.4 out of 10 from a total of 12 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 8% reported a negative effect. |
Kesimpta has an average rating of 6.9 out of 10 from a total of 75 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 19% reported a negative effect. |
Copaxone has an average rating of 7.5 out of 10 from a total of 133 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Cyclophosphamide side effects |
View all Kesimpta side effects |
View all Copaxone side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Cyclophosphamide prices |
View all Kesimpta prices |
View all Copaxone prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Frindovyx | Other ofatumumab brands include: Arzerra | Other glatiramer brands include: Glatopa | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
6.5 hours |
1476 hours |
1 hour |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 406 drugs are known to interact with Cyclophosphamide:
|
A total of 177 drugs are known to interact with Kesimpta:
|
A total of 1 drugs are known to interact with Copaxone:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
November 16, 1959 |
N/A |
December 20, 1996 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Benlysta
Benlysta infusion is used to treat active systemic lupus erythematosus (SLE) and active lupus ...
Kesimpta
Kesimpta (ofatumumab) is used to treat relapsing forms of multiple sclerosis. Includes Kesimpta ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Jaypirca
Jaypirca (pirtobrutinib) is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes ...
Tavneos
Tavneos (avacopan) is a C5a receptor antagonist used for severe active ANCA-associated vasculitis ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.